 Home > Medical News > Latest Medical News > Arnold Pharma submits clinical application for new drug AN4005 to FDA

Arnold Pharma submits clinical application for new drug AN4005 to FDA

 Last Update: 2021-06-02
 Source: Internet
 Author: User

Tags

topiramate half life

half life lab

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 20, Arnold Pharma announced that it had submitted a clinical trial application (IND) for its original innovative drug oral PD-L1 inhibitor AN4005 to the US FDA.

AN4005 can effectively induce and stabilize the formation and dimerization of PD-L1 dimers, thereby effectively destroying the interaction between PD-1/PD-L1 proteins.

Compared with monoclonal antibodies, small molecule PD-(L)1 inhibitors are expected to bring greater benefits.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.